Suppr超能文献

估算不同定义和样本选择形式下的新冠长期症状患病率。

Estimating long COVID-19 prevalence across definitions and forms of sample selection.

作者信息

Lovaglio Pietro Giorgio, Borgonovo Fabio, Manzo Margiotta Alessandro, Mowafy Mohamed, Colaneri Marta, Bandera Alessandra, Gori Andrea, Capetti Amedeo Ferdinando

机构信息

Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy.

Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.

出版信息

Front Epidemiol. 2025 May 30;5:1597799. doi: 10.3389/fepid.2025.1597799. eCollection 2025.

Abstract

INTRODUCTION

Long COVID (LC) is a multisystem condition with prolonged symptoms persisting beyond acute SARS-CoV-2 infection. However, prevalence estimates vary widely due to differences in case definitions and sampling methodologies. This study aims to determine the prevalence of LC across different definitions and correct for selection bias using advanced statistical modeling.

METHODS

We conducted a retrospective, observational study at Luigi Sacco Hospital (Milan, Italy), analyzing 3,344 COVID-19 patients from two pandemic waves (2020-2021). Participants included 1,537 outpatients from the ARCOVID clinic and 1,807 hospitalized patients. LC was defined based on WHO and NICE criteria, as well as two alternative definitions: symptoms persisting at 3 and 6 months post-infection. We used a bivariate censored Probit model to account for selection bias and estimate adjusted LC prevalence.

RESULTS

LC prevalence varied across definitions: 67.4% (WHO), 76.3% (NICE), 80.2% (3 months), and 79.6% (6 months). Adjusted prevalence estimates remained consistent across definitions. The most common symptoms were fatigue (58.6%), dyspnea (41.1%), and joint/muscle pain (39.2%). Risk factors included female sex (OR 2.165-2.379), metabolic disease (OR 1.587-1.629), and older age (40-50 years, OR 1.847). Protective factors included antiplatelets (OR 0.640-0.689), statins (OR 0.616), and hypoglycemics (OR 0.593-0.706). Vaccination, hydroxychloroquine, and antibiotics were associated with an increased risk of LC. Selection bias significantly influenced prevalence estimates, underscoring the need for robust statistical adjustments.

DISCUSSION

Our findings highlight the high prevalence of LC, particularly among specific subgroups, with strong selection effects influencing outpatient participation. Differences in prevalence estimates emphasize the impact of case definitions and study designs on LC research. The identification of risk and protective factors supports targeted interventions and patient management strategies.

CONCLUSION

This study provides one of the most comprehensive analyses of LC prevalence while accounting for selection bias. Our findings call for standardized LC definitions, improved epidemiological methodologies, and targeted prevention strategies. Future research should explore prospective cohorts to refine LC prevalence estimates and investigate long-term health outcomes.

摘要

引言

长期新冠(LC)是一种多系统疾病,其症状在急性SARS-CoV-2感染后持续很长时间。然而,由于病例定义和抽样方法的差异,患病率估计值差异很大。本研究旨在确定不同定义下LC的患病率,并使用先进的统计模型校正选择偏倚。

方法

我们在意大利米兰的路易吉·萨科医院进行了一项回顾性观察研究,分析了来自两个疫情波(2020 - 2021年)的3344例新冠患者。参与者包括ARCOVID诊所的1537名门诊患者和1807名住院患者。LC根据世界卫生组织(WHO)和英国国家卫生与临床优化研究所(NICE)的标准以及另外两个替代定义来定义:感染后3个月和6个月持续存在的症状。我们使用二元删失Probit模型来校正选择偏倚并估计调整后的LC患病率。

结果

LC患病率因定义而异:67.4%(WHO)、76.3%(NICE)、80.2%(3个月)和79.6%(6个月)。调整后的患病率估计值在不同定义下保持一致。最常见症状为疲劳(58.6%)、呼吸困难(41.1%)和关节/肌肉疼痛(39.2%)。危险因素包括女性(比值比2.165 - 2.379)、代谢疾病(比值比1.587 - 1.629)和年龄较大(40 - 50岁,比值比1.847)。保护因素包括抗血小板药物(比值比0.640 - 0.689)、他汀类药物(比值比0.616)和降糖药(比值比0.

相似文献

1
Estimating long COVID-19 prevalence across definitions and forms of sample selection.
Front Epidemiol. 2025 May 30;5:1597799. doi: 10.3389/fepid.2025.1597799. eCollection 2025.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.
Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD013665. doi: 10.1002/14651858.CD013665.
4
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2021 Mar 24;3(3):CD013705. doi: 10.1002/14651858.CD013705.pub2.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2.
9
Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review.
JAMA Netw Open. 2021 May 3;4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417.
10
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.

引用本文的文献

1
Exploring the psychological impact of long COVID: symptoms, mechanisms, and treatments.
Front Psychiatry. 2025 Aug 19;16:1555370. doi: 10.3389/fpsyt.2025.1555370. eCollection 2025.

本文引用的文献

1
Neurologic Manifestations of Long COVID Disproportionately Affect Young and Middle-Age Adults.
Ann Neurol. 2025 Feb;97(2):369-383. doi: 10.1002/ana.27128. Epub 2024 Nov 22.
5
Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022.
MMWR Morb Mortal Wkly Rep. 2024 Feb 15;73(6):135-136. doi: 10.15585/mmwr.mm7306a4.
6
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.
Infection. 2024 Feb;52(1):43-58. doi: 10.1007/s15010-023-02154-0. Epub 2023 Dec 19.
7
True prevalence of long-COVID in a nationwide, population cohort study.
Nat Commun. 2023 Nov 30;14(1):7892. doi: 10.1038/s41467-023-43661-w.
8
SARS-CoV-2 Reinfections and Long COVID in the Post-Omicron Phase of the Pandemic.
Int J Mol Sci. 2023 Aug 19;24(16):12962. doi: 10.3390/ijms241612962.
9
Post-COVID care delivery: The experience from an Irish tertiary centre's post-COVID clinic.
PLoS One. 2023 Aug 11;18(8):e0289245. doi: 10.1371/journal.pone.0289245. eCollection 2023.
10
Prevalence of Long COVID Symptoms Related to SARS-CoV-2 Strains.
Life (Basel). 2023 Jul 13;13(7):1558. doi: 10.3390/life13071558.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验